Dermatology, FDA Approval, Genetic Disease and Life Science

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Dermatology

FDA Approval

Genetic Disease

Life Science

Vyjuvek Gets FDA Nod as First Topical Gene Therapy for Rare Skin Disease

XTalks

MAY 26, 2023

Krystal Biotech’s Vyjuvek has been awarded US Food and Drug Administration (FDA) approval to make it the first topical gene therapy for the treatment of wounds in patients with the rare, often debilitating skin disease dystrophic epidermolysis bullosa (DEB).

Gene Therapy

Gene Therapy Gene FDA Approval Dermatology

Spevigo Becomes First Treatment Option for Generalized Pustular Psoriasis Flares

XTalks

SEPTEMBER 22, 2022

On September 1, 2022, Boehringer Ingelheim Pharmaceuticals announced in a press release that the US Food and Drug Administration (FDA) approved Spevigo (spesolimab-sbzo) intravenous injections for GPP flares in adults. Spevigo is the first approved treatment option for GPP in adults. A Promising Treatment for a Rare Disease.

FDA Approval

FDA Approval Clinical Trials Clinical Trials Dermatology

Clinical Research Informer

Vyjuvek Gets FDA Nod as First Topical Gene Therapy for Rare Skin Disease

Spevigo Becomes First Treatment Option for Generalized Pustular Psoriasis Flares

Stay Connected